OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Antonarakis on the Utility of Sipuleucel-T Plus Radium-223 in Nonmetastatic CRPC

March 31st 2020

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Dr. Chen on the Impact of the Pivotal IMpower133 Trial on SCLC

March 31st 2020

Hui-Zi Chen, MD, PhD, discusses how the IMpower133 trial has helped to propel the field of small-cell lung cancer forward.

Dr. Agarwal on the Safety of Cabozantinib/Atezolizumab in mCRPC

March 31st 2020

Neeraj Agarwal, MD, discusses the safety profile ofcabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Using Steroids to Manage Immunotherapy-Associated AEs in Melanoma

March 30th 2020

Kathleen Madden, FNP, MSN, AOCNP, APHN, discusses how to judiciously use steroids to manage adverse events in patients with melanoma who are receiving immunotherapy.

Dr. Schmaier on Managing Thrombosis in Hematologic Malignancies

March 28th 2020

Alvin H. Schmaier, MD, discusses managing thrombosis in patients with hematologic malignancies.

Dr. Radich on the Utility of MRD in Hematologic Malignancies

March 28th 2020

Jerald P. Radich, MD, discusses the utility of minimal residual disease in hematologic malignancies.

Dr. Lonial on the Role of Targeted Therapy in AML and ALL

March 28th 2020

Sagar Lonial, MD, FACP, discusses the role of targeted therapy in acute myeloid leukemia and acute lymphoblastic leukemia.

Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPC

March 28th 2020

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Hussain on the Implications of the PROfound Trial in mCRPC

March 28th 2020

Maha Hussain, MD, FACP, FASCO, Genevieve E. Teuton Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, and Deputy Director at the Robert H. Lurie Comprehensive Cancer Center, of Northwestern University Feinberg School of Medicine, discusses the implications of the phase III PROfound trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Parker on the Results of the RADICALS-RT Trial in Prostate Cancer

March 28th 2020

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the results of the phase III RADICALS-RT trial in prostate cancer.

Dr. Garcia on Efficacy of Navitoclax in Ruxolitinib-Resistant Myelofibrosis

March 28th 2020

Jacqueline S. Garcia, MD, discusses results from a phase II trial examining the addition of the BCL-2/BCL-XL inhibitor navitoclax to ruxolitinib in patients with primary or secondary myelofibrosis with acquired resistance to ruxolitinib.

Dr. Overman on Choosing Between Regorafenib and TAS-102 in CRC

March 28th 2020

Michael J. Overman, MD, discusses factors to consider when choosing between regorafenib and TAS-102 in the third-line treatment of patients with colorectal cancer.

Dr. Tagawa on Remaining Questions With PSMA-Targeted Radionuclide Therapy in mCRPC

March 28th 2020

Scott T. Tagawa, MD, MS, discusses remaining questions regarding treatment selection and PSMA imaging in metastatic castration-resistant prostate cancer.

Dr. Antonarakis on PD-1/PD-L1 Monotherapy in Prostate Cancer

March 28th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Dr. Nagalla on Need for Timely Assays for DOACs in MPNs

March 27th 2020

Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRC

March 27th 2020

Douglas A. Nelson, MD, discusses results from the CheckMate-142 in metastatic colorectal cancer.

Dr. Burke on the Ongoing First-MIND Trial With Tafasitamab in DLBCL

March 27th 2020

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

Dr. Viprakasit on the Results of the BELIEVE Trial With Luspatercept in Beta-Thalassemia

March 27th 2020

Vip Viprakasit, MD, DPhil, professor of Pediatrics, and director, Thalassemia Research, Siriraj-Thalassemia Center, Siriaj Hospital, discusses the results of the multicenter BELIEVE trial with luspatercept (Reblozyl) in adult patients with β-thalassemia.

Dr. Schuster on GO29781 Trial With Mosunetuzumab in NHL

March 27th 2020

Stephen J. Schuster, MD, director of the Lymphoma Program, director of Translational Research, Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clincai Care and Research at University of Pennsylvania, discusses the results of the phase I/Ib dose-escalation GO29781 trial (NCT02500407) with mosunetuzumab in relapsed/refractory non-Hodgkin lymphoma (NHL).

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2020

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.